Breakthrough eye cancer drug now tested to stop deadly recurrence
NCT ID NCT06246149
Summary
This study tests whether a drug called tebentafusp can prevent cancer from returning in people with high-risk eye melanoma after their initial treatment. About 290 patients who have completed treatment for their primary eye tumor will be randomly assigned to either receive the drug or be monitored with observation only. The goal is to see if the drug reduces the risk of the cancer coming back, building on its success in treating advanced cases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Antoine Lacassagne
RECRUITINGNice, FR 06189, France
Contact
-
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin
RECRUITINGBerlin, 12200, Germany
Contact
-
Cliniques Universitaires Saint-Luc
RECRUITINGBrussels, 1200, Belgium
Contact
-
East and North Hertfordshire NHS Trust - Mount Vernon Hospital
RECRUITINGNorthwood, HA6 2RN, United Kingdom
Contact
-
Erasmus MC
RECRUITINGRotterdam, NL 3015 GD, Netherlands
Contact
-
Hospital Clinico Universitario De Valladolid
RECRUITINGValladolid, 47003, Spain
Contact
-
Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)
RECRUITINGL'Hospitalet de Llobregat, 08908, Spain
Contact
-
Institut Curie - Hôpital de Paris
RECRUITINGParis, 75248, France
Contact
-
Leiden University Medical Centre
RECRUITINGLeiden, 2300, Netherlands
Contact
-
Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology
RECRUITINGWarsaw, 02 781, Poland
Contact
-
Sahlgrenska Universitetssjukhuset
RECRUITINGGothenburg, SE 413 45, Sweden
Contact
-
The Clatterbridge cancer Center NHS foundation Trust - Clatterbridge Cancer Center - Liverpool
RECRUITINGLiverpool, GB L7 8YA, United Kingdom
Contact
-
Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center
RECRUITINGHamburg, 20246, Germany
Contact
-
Universitaetsklinikum Heidelberg - Frauenklinik / Hautklinik
RECRUITINGHeidelberg, DE 69120, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.